Case Report

The dreaded osteonecrosis of femur following chronic steroid therapy: a case series from a dermatologist’s eye

Abiram Ponnuswami*, Cordelia Babitha S., Krishnakanth Muralidhar, Murugan Sundaram

INTRODUCTION

Corticosteroid therapy, irrespective of the mode of administration, systemic- oral or parenteral or topical therapy - has its own associated risks of side-effects. Avascular necrosis of the femoral head is one of the universally recognized side-effects of steroid therapy. The etiology of avascular necrosis is multifactorial and ranges from fracture of the neck of femur to traumatic dislocation of hip to slipped femoral capital epiphysis. It has been reported to occur secondary to osteotomy, sickle cell anemia, alcoholism, autoimmune connective tissue disorder like rheumatoid arthritis, lupus erythematosus, pancreatitis, occlusive vascular disease, phaeochromocytoma, infections, radiation, Gaucher's disease, renal transplantation, Caisson's disease and even in pregnancy.

Amongst the dermatological diseases, avascular necrosis of the femoral head has been reported more commonly in SLE, Psoriasis, Pemphigus - secondary to even potent topical corticosteroids such as clobetasol cream. Avascular necrosis manifests clinically as insidious onset of pain, aggravated by movements, relieved by rest, with occasional radiation down the affected limb. A slight limp, often unilateral, with limitation of abduction and adduction movements to a variable degree is characteristic. Atrophy of the proximal muscles may be seen. Femoral head has a precarious blood supply leading to a wedge-shaped area of avascular necrosis. Necrosis radiologically appears as a mottled area and the fibrous zone as a radiolucent band with demineralization of the uninvolved bone.

The pathophysiological mechanisms include increase in the intra-osseous pressure resulting from lipocyte hypertrophy, deposition of fat in the marrow spaces of the skeleton in patients who were treated with steroids, particularly in individuals who underwent short-term treatment with high-dose steroids, blood stasis and ischemia in the trabecular bone, increase in the osteocyte apoptosis owing to micro damage in the bone could have a role too.

Whatever be the pathologic etiology, so far, an exact relationship between the dose and the mode of administration, and the risk of developing avascular necrosis, has not been determined.
CASE REPORTS

Case 1

A 39 years old female, a known case of Pemphigus vulgaris, on prolonged steroid therapy for one year and six months, due to periodic exacerbations, comes with complaints of right sided hip pain. She was initially on 40 mg/day prednisolone which was then tapered and currently on 10 mg/day. On obtaining opinion from the orthopaedician and evaluating with the bone mineral density and DEXA scan, osteopenia and osteonecrosis was diagnosed in the right hip joint (Figure 1).

CASE REPORTS

Case 2

A 44 years old female, a known case of Pemphigus foliaceous for the past 1 year, comes with complaints of left sided hip pain for the past six months. She was initially on 40 mg/day prednisolone which was tapered and now currently on 10 mg/day prednisolone on alternate days. Orthopaedician opinion was sought and following investigations, osteonecrosis of left hip joint was made (Figure 2).

Case 3

A 39 years old female with discoid lupus erythematosus on prolonged oral steroid therapy, presented with restriction of movements of bilateral hip joints. She was irregular on follow up and kept consuming 10 mg/day prednisolone for the past six months. Based on bone mineral density and DEXA scan, avascular necrosis of left hip joint and osteopenia of right hip joint was made (Figure 3).

Case 4

A 39 years old homemaker with Pemphigus vulgaris, with unsupervised steroid intake for 3 years, reports with pain in hip joint on both sides. Following DEXA scan, osteonecrosis of both hip joints was made (Figure 4).

DISCUSSION

The first patient of pemphigus (described by Pietrogrande and Mastronarino), was a woman, who developed avascular necrosis after four years of therapy with 100 mg cortisone acetate daily.10
The risk factors for avascular necrosis of femur include: high dose systemic steroids, chronic alcoholism, smoking and hip dislocations and fracture.

It is useful to note that steroids greater than 10 mg/day for 6 months or equivalent, can cause osteonecrosis. Also, osteoporotic changes can start as early as 2 months with 20 mg dose. Certain risk factors pertaining to the particular disease entity might enhance the risk e.g., hyperuricemia in psoriatics, hyperlipidemias in SLE etc.

Candidates requiring monitoring include those who require steroids for >3 months or 10 mg/day for 6 months or equivalent.

According to the American College of Rheumatology guidelines (2017), steps to prevent AVN include: BMD of lumbar spine/hip - before initiating therapy, BMD of lumbar spine/hip - every 6 months, BMD every year - if preventive measures are undertaken, calcium - 1000 to 1500 mg/day, vitamin D3 - 800 IU/day, gonadal hormones - oestrogen, SERM - raloxifene 60 mg/day, bazedoxifene 20 to 40 mg/day, bisphosphonates - alendronate 10 mg/day, ibandronate 2 mg/day, thiazides and sodium restriction, calcitinin – 200 IU/week and anabolic steroids (second line).

Amongst the non-traumatic causes of avascular necrosis of the femur, patients of SLE who are treated with corticosteroids have been reported to have a high relative risk of developing avascular necrosis with a reported frequency of 5-40%. One study in SLE patients reviewed the clinical features of the disease and the laboratory data of the patients of SLE at the time of developing avascular necrosis and the dose of steroids and found that a rash introduction of high-dose steroids (>30 g/day) prednisolone without “steroid preloading” was associated with a higher risk of avascular necrosis and suggested that a minimum/moderate amount of glucocorticoid preloading lessens the risk of avascular necrosis.

CONCLUSION

Systemic corticosteroids entail increased risk of developing osteonecrosis with cases being reported as early as 12 months into steroid therapy (on an average dose of 20 mg steroids). Hence it is important to monitor steroid regimen judiciously and switch over to steroid sparing agents promptly. Calcium and bisphosphonates supplementation, restriction of weight bearing and periodic bone mineral density and radiological checkup are of paramount importance.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES